SBC Medical Group (NASDAQ:SBC) Posts Quarterly Earnings Results, Beats Estimates By $0.01 EPS

SBC Medical Group (NASDAQ:SBC) released its earnings results on Friday. The company reported $0.14 EPS for the quarter, beating analysts’ consensus estimates of $0.13 by $0.01, FiscalAI reports. SBC Medical Group had a return on equity of 24.17% and a net margin of 24.28%.The company had revenue of $39.57 million during the quarter, compared to analysts’ expectations of $45.19 million.

Here are the key takeaways from SBC Medical Group’s conference call:

• Average revenue per customer rebounded to $316 in Q4 (+11% YoY), and management says customer growth and improving unit economics are moving together—management views this as a potential inflection point for long‑term growth.
• Full‑year revenue declined 15% to $174 million, driven by 2024 restructuring and a fee‑structure change in April 2025, indicating material top‑line pressure despite operational actions.
• Profitability strengthened as net income rose 9% to $51 million, EPS increased 4% to $0.50, and EBITDA was $70 million with a 40.4% margin, largely due to the non‑recurrence of prior one‑time listing and revaluation costs.
• Management is rolling out strategic initiatives—SBC Wellness 2.0 (longevity + AI), a multi‑brand dermatology strategy, and early international moves (e.g., OrangeTwist)—which broaden addressable markets but are still early stage.
• Capital policy prioritizes growth and active M&A using abundant cash (with a flexible, approved share buyback program not yet executed), giving the company strategic optionality but no near‑term deployment specifics.

SBC Medical Group Stock Down 1.6%

NASDAQ SBC traded down $0.06 during mid-day trading on Friday, reaching $3.74. The stock had a trading volume of 7,082 shares, compared to its average volume of 29,365. The stock has a market cap of $383.43 million, a PE ratio of 9.11 and a beta of 1.19. SBC Medical Group has a 1 year low of $2.91 and a 1 year high of $5.75. The company has a debt-to-equity ratio of 0.07, a current ratio of 5.10 and a quick ratio of 5.06. The company has a fifty day moving average price of $4.13 and a 200 day moving average price of $4.05.

Insider Buying and Selling

In other SBC Medical Group news, CEO Yoshiyuki Aikawa sold 4,422,900 shares of the stock in a transaction on Friday, March 6th. The stock was sold at an average price of $2.12, for a total transaction of $9,376,548.00. Following the sale, the chief executive officer directly owned 861,600 shares in the company, valued at approximately $1,826,592. This trade represents a 83.70% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 89.47% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Geode Capital Management LLC increased its holdings in SBC Medical Group by 37.6% in the 4th quarter. Geode Capital Management LLC now owns 262,043 shares of the company’s stock worth $1,129,000 after buying an additional 71,664 shares in the last quarter. Millennium Management LLC bought a new position in SBC Medical Group during the 3rd quarter valued at about $219,000. Charles Schwab Investment Management Inc. lifted its stake in SBC Medical Group by 91.6% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 27,341 shares of the company’s stock valued at $118,000 after acquiring an additional 13,074 shares during the period. New York State Common Retirement Fund purchased a new stake in shares of SBC Medical Group during the 2nd quarter valued at about $104,000. Finally, Barclays PLC grew its stake in shares of SBC Medical Group by 123.7% in the fourth quarter. Barclays PLC now owns 17,779 shares of the company’s stock worth $77,000 after acquiring an additional 9,831 shares during the period. 60.82% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the company. BTIG Research initiated coverage on SBC Medical Group in a report on Friday, March 6th. They issued a “buy” rating and a $8.00 price objective for the company. Weiss Ratings restated a “sell (d+)” rating on shares of SBC Medical Group in a report on Monday, December 29th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $8.50.

About SBC Medical Group

SBC Medical Group, Inc is a publicly traded healthcare management services company listed on the Nasdaq under the ticker SBC. The company specializes in supporting in-office ancillary service providers by offering a suite of administrative and operational solutions designed to streamline practice management and enhance revenue performance. Its core mission is to help physician practices, imaging centers and other ancillary service providers focus on patient care while outsourcing complex back-office functions.

The company’s primary offerings include revenue cycle management, medical billing and coding, compliance oversight and transcription services.